Hua Medicine (HUMDF) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Hm-002-1005 | Diabetes Mellitus, Type Ii | Phase I | Completed | Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus | Apr 30, 2024 | ― |
| Dorzagliatin Tablets | Type2diabetes | Phase IV | Completed | A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes | Feb 05, 2024 | ― |
| Empagliflozin, Dorzagliatin | Patients | Phase I | Completed | Drug Interaction Study Between Dorzagliatin and Empagliflozin | Dec 27, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Hm-002-1005 | Phase I | Diabetes Mellitus, Type Ii | Completed | Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus | Apr 30, 2024 | ― |
| Dorzagliatin Tablets | Phase IV | Type2diabetes | Completed | A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes | Feb 05, 2024 | ― |
| Empagliflozin, Dorzagliatin | Phase I | Patients | Completed | Drug Interaction Study Between Dorzagliatin and Empagliflozin | Dec 27, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Hua Medicine (HUMDF) have in its pipeline
Hua Medicine HUMDF is currently developing the following drugs: Hm-002-1005, Dorzagliatin Tablets, Empagliflozin, Dorzagliatin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.